About 44,378 results

ALLMedicine™ Multiple Myeloma Center

Research & Reviews  12,658 results

Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myelom...
European Journal of Haematology; Del Giudice ML, Gozzetti A et. al.

Jun 25th, 2022 - We investigate safety and efficacy in common clinical practice of the combination of carfilzomib and dexamethasone (Kd56) approved for the ENDEAVOR trial for the treatment of relapsed or refractory multiple myeloma. We retro-prospective analyzed 7...

GPRC5D-Directed CAR Yields 100% Response Rate.
Cancer Discovery;

Jun 25th, 2022 - Patients with refractory or relapsed multiple myeloma usually develop resistance to the two approved BCMA-targeting chimeric antigen receptor (CAR) T cells. A preliminary study of a new CAR T-cell therapy that zeroes in on the GPRC5D protein on mu...

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Jun 24th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Jun 24th, 2022 - Background: Graft versus host disease (GVHD) and impaired immune reconstitution are major transplant complications and barriers to improving outcomes after allogeneic hematopoietic stem cell transplantation (alloHSCT) for hematologic malignancies....

see more →

Guidelines  36 results

Management of herpesvirus reactivations in patients with solid tumours and hematologic ...
Annals of Hematology; Henze L, Buhl C et. al.

Jan 8th, 2022 - Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy ...

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive C...
Clinical Lymphoma, Myeloma & Leukemia; LeBlanc R, Bergstrom DJ et. al.

Aug 31st, 2021 - Multiple myeloma (MM) is a hematological cancer associated with significant symptomatic burden. Bone disease, renal insufficiency, cytopenias, infection, and peripheral neuropathy, among other disease manifestations and complications, impair patie...

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and fo...
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.

Feb 8th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Dec 8th, 2020 - Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, ...

see more →

Drugs  158 results see all →

Clinicaltrials.gov  2,374 results

Agriculture Health Study

Jun 24th, 2022 - The "Agricultural Health Study" (AHS) is a collaborative effort between the National Cancer Institute and the National Institute of Environmental Health Sciences. The U.S. Environmental Protection Agency and the National Institute for Occupational...

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-...

Jun 24th, 2022 - OUTLINE: This is a dose-escalation study of ²¹¹At-OKT10-B10. Patients are assigned to 1 of 2 arms. ARM A: Patients with HLA-matched related or unrelated donors receive ²¹¹At-OKT10-B10 intravenously (IV) on day -7 (day -10 to -5) and fludarabine IV...

Tissue Collection for Studies of Lymph Cancer

Jun 24th, 2022 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study

Jun 24th, 2022 - We propose to conduct a molecular epidemiology study with a subset of participants in the Agricultural Health Study (AHS), a prospective cohort of 57,310 licensed pesticide applicators in Iowa and North Carolina. Blood and urine samples will be co...

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Jun 24th, 2022 - This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately...

see more →

News  2,502 results

Slow Progress, but Many Disparities in Cancer Burden Persist

Jun 17th, 2022 - Cancer continues to exact a high and disproportionate toll on racial and ethnic minorities and other medically underserved populations in the United States, despite some progress in reducing disparities, according to the American Association for C...

New CAR-T Therapy Elicits Strong Response in Multiple Myeloma

Jun 16th, 2022 - All 30 patients with relapsed/refractory multiple myeloma who received a new CAR T-cell therapy, ARI0002h, responded to the investigational agent, with almost two thirds achieving complete remission at 16 months, new data show. Most patients did n...

Teclistamab Shows 'Promising' Activity in R/R Multiple Myeloma

Jun 6th, 2022 - A weekly subcutaneous dose of teclistamab resulted in high response rates among adults with relapsed or refractory multiple myeloma, based on data from 165 patients in the MajesTEC-1 study presented at the annual meeting of the American Society of...

‘Very impressive’ data promise new blood cancer option
Heidi Splete

Jun 5th, 2022 - A weekly subcutaneous dose of teclistamab resulted in high response rates among adults with relapsed or refractory multiple myeloma, based on data from 165 patients in the MajesTEC-1 study presented at the annual meeting of the American Society of.

First-Line Treatment in Newly Diagnosed Multiple Myeloma

Jun 5th, 2022 - New results from a trial in patients with newly diagnosed multiple myeloma offer some answers to questions about which treatment route to choose. The trial, known as DETERMINATION, found that newly diagnosed patients treated with a triplet of drug...

see more →

Patient Education  23 results see all →